Cargando…

Understanding noninferiority trials

Noninferiority trials test whether a new experimental treatment is not unacceptably less efficacious than an active control treatment already in use. With continuous improvements in health technologies, standard care, and clinical outcomes, the incremental benefits of newly developed treatments may...

Descripción completa

Detalles Bibliográficos
Autor principal: Hahn, Seokyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Pediatric Society 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510268/
https://www.ncbi.nlm.nih.gov/pubmed/23227058
http://dx.doi.org/10.3345/kjp.2012.55.11.403
_version_ 1782251445984165888
author Hahn, Seokyung
author_facet Hahn, Seokyung
author_sort Hahn, Seokyung
collection PubMed
description Noninferiority trials test whether a new experimental treatment is not unacceptably less efficacious than an active control treatment already in use. With continuous improvements in health technologies, standard care, and clinical outcomes, the incremental benefits of newly developed treatments may be only marginal over existing treatments. Sometimes assigning patients to a placebo is unethical. In such circumstances, there has been increasing emphasis on the use of noninferiority trial designs. Noninferiority trials are more complex to design, conduct, and interpret than typical superiority trials. This paper reviews the concept of noninferiority trials and discusses some important issues related to them.
format Online
Article
Text
id pubmed-3510268
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher The Korean Pediatric Society
record_format MEDLINE/PubMed
spelling pubmed-35102682012-12-07 Understanding noninferiority trials Hahn, Seokyung Korean J Pediatr Review Article Noninferiority trials test whether a new experimental treatment is not unacceptably less efficacious than an active control treatment already in use. With continuous improvements in health technologies, standard care, and clinical outcomes, the incremental benefits of newly developed treatments may be only marginal over existing treatments. Sometimes assigning patients to a placebo is unethical. In such circumstances, there has been increasing emphasis on the use of noninferiority trial designs. Noninferiority trials are more complex to design, conduct, and interpret than typical superiority trials. This paper reviews the concept of noninferiority trials and discusses some important issues related to them. The Korean Pediatric Society 2012-11 2012-11-23 /pmc/articles/PMC3510268/ /pubmed/23227058 http://dx.doi.org/10.3345/kjp.2012.55.11.403 Text en Copyright © 2012 by The Korean Pediatric Society http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Hahn, Seokyung
Understanding noninferiority trials
title Understanding noninferiority trials
title_full Understanding noninferiority trials
title_fullStr Understanding noninferiority trials
title_full_unstemmed Understanding noninferiority trials
title_short Understanding noninferiority trials
title_sort understanding noninferiority trials
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510268/
https://www.ncbi.nlm.nih.gov/pubmed/23227058
http://dx.doi.org/10.3345/kjp.2012.55.11.403
work_keys_str_mv AT hahnseokyung understandingnoninferioritytrials